Document Detail


Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
MedLine Citation:
PMID:  21438938     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic medical conditions such as opioid dependence require evidence-based treatment recommendations. However, pregnant women are under-represented in clinical trials. We describe the first within-subject comparison of maternal and neonatal outcomes for methadone- versus buprenorphine-exposed pregnancies. Although methadone is the established treatment of pregnant opioid-dependent women, recent investigations have shown a trend for a milder neonatal abstinence syndrome (NAS) under buprenorphine. However, it is not only the choice of maintenance medication that determines the occurrence of NAS; other factors such as maternal metabolism, illicit substance abuse and nicotine consumption also influence its severity and duration and represent confounding factors in the assessment of randomized clinical trials. CASE SERIES DESCRIPTION: Three women who were part of the European cohort of a randomized, double-blind multi-center trial with a contingency management tool [the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study], each had two consecutive pregnancies and were maintained on either methadone or buprenorphine for their first and then the respective opposite, still-blinded medication for their second pregnancy. Birth measurements, the total neonatal abstinence score, the total amounts of medication used to treat NAS and the days of NAS treatment duration were assessed.
RESULTS: Both medications were effective and safe in reducing illicit opioid relapse and avoiding preterm labor. Methadone maintenance yielded to a significantly higher neonatal birth weight. Data patterns suggest that buprenorphine exposure was associated with lower neonatal abstinence syndrome (NAS) scores. Findings from this unique case series are consistent with earlier reports using between-group analyses.
CONCLUSIONS: Buprenorphine has the potential to become an established treatment alternative to methadone for pregnant opioid-dependent women. Under special consideration of ethical boundaries, psychopharmacological treatment during pregnancy must be addressed as an integral part of clinical research projects in order to optimize treatment for women and neonates.
Authors:
Annemarie Unger; Reinhold Jagsch; Hendree Jones; Amelia Arria; Harald Leitich; Klaudia Rohrmeister; Constantin Aschauer; Berndadette Winklbaur; Andjela Bäwert; Gabriele Fischer
Related Documents :
18281788 - Eyelid phenol peel: an important adjunct to blepharoplasty.
21120498 - The treatment of rheumatoid arthritis during pregnancy.
22617858 - Maternal and fetal microchimerism in granulocytes.
24626668 - Case for diagnosis.
16148158 - Uterine nk cells mediate inflammation-induced fetal demise in il-10-null mice.
17557378 - Sonographic estimation of fetal weight: comparison of bias, precision and consistency u...
Publication Detail:
Type:  Case Reports; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2011-05-12
Journal Detail:
Title:  Addiction (Abingdon, England)     Volume:  106     ISSN:  1360-0443     ISO Abbreviation:  Addiction     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-03     Completed Date:  2011-09-20     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  9304118     Medline TA:  Addiction     Country:  England    
Other Details:
Languages:  eng     Pagination:  1355-62     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors, Addiction © 2011 Society for the Study of Addiction.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Analgesics, Opioid / therapeutic use*
Birth Weight / drug effects
Buprenorphine / therapeutic use*
Double-Blind Method
Female
Humans
Infant, Newborn
Male
Methadone / therapeutic use*
Neonatal Abstinence Syndrome / epidemiology*,  etiology,  prevention & control
Opiate Substitution Treatment / methods
Opioid-Related Disorders / complications,  drug therapy*
Pregnancy
Pregnancy Complications / drug therapy*
Severity of Illness Index
Smoking / epidemiology
Treatment Outcome
Young Adult
Grant Support
ID/Acronym/Agency:
R01 DA015764/DA/NIDA NIH HHS; R01 DA018417/DA/NIDA NIH HHS; R01 DA018417-01/DA/NIDA NIH HHS; R01 DA018417-02/DA/NIDA NIH HHS; R01 DA018417-03/DA/NIDA NIH HHS; R01 DA018417-04/DA/NIDA NIH HHS; R01 DA018417-04S1/DA/NIDA NIH HHS; R01 DA018417-05/DA/NIDA NIH HHS; R01DA018417/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 40D3SCR4GZ/Buprenorphine; UC6VBE7V1Z/Methadone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cannabis and social welfare assistance: a longitudinal study.
Next Document:  Relative performance of common biochemical indicators in detecting cigarette smoking.